Pidilizumab in the treatment of diffuse large B-cell lymphoma
- ,
- Leo I. Gordon(corresponding author)
- Northwestern University
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewAbstract
<p>Introduction: The programmed death-1 (PD-1) immune checkpoint pathway is an emerging target in the treatment of hematologic malignancies. Pidilizumab is an mAb that binds to PD-1 and is a safe and well-tolerated therapy. Recent data have shown clinical activity utilizing this strategy in diffuse large B-cell lymphoma (DLBCL).Areas covered: The role of PD-1 expression in hematologic malignancies is explored. Recent clinical trials including the results of a Phase I trial in hematologic malignancies and a Phase II trial of pidilizumab following autologous hematopoietic stem-cell transplant (AHSCT) are reviewed.Expert opinion: We review data that suggest that PD-1 is a promising target in the treatment and management of DLBCL. Changes in immune subsets following administration of pidilizumab are felt to represent on-target responses. The improvement in progression-free survival (PFS) following AHSCT supports a response to therapy. Importantly, the improvement in PFS for patients with positive FDG-PET/CT following AHSCT indicating residual disease further supports direct activity of pidilizumab in DLBCL.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 1361-1368 (8 pages)Journal (Volume, Issue Number)
Expert Opinion on Biological Therapy (Volume 14, Issue 9)Publication milestones
- Published - 09/2014
Publication status
Published - 09/2014
ISSN
1471-2598Publication IDs
- Scopus: 84905816355
- PubMed: 25056108
Publication metrics
Metrics
SciVal
FWCI
0.45
SciVal
Author count
2
SciVal
citations
16
SciVal
Paper percentile
77
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Captures
50
Citation count
19
